Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
{{output}}
Chromosomal rearrangements of the RET (rearranged during transfection) gene are detected in approximately 1-2% of non-small cell lung cancers (NSCLC) and have function as oncogenic driver genes. Selpercatinib is a highly effective RET inhibitor for RET-rearran... ...
